Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maximilian Lennartz

Showing results (81-90 of 113) with videos related to

Pageof 12
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology|January 29, 2022
Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligenceDavid Dum, Tjark L C Henke, Tim Mandelkow, et al.
Scientific Reports|August 9, 2023
Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroidMaximilian Lennartz, Henrietta Csomós, Viktoria Chirico, et al.
Plos One|June 28, 2023
CELA3B immunostaining is a highly specific marker for acinar cell carcinoma of the pancreasRia Uhlig, Nina Bröker, Sören Weidemann, et al.
Virchows Archiv : an International Journal of Pathology|June 15, 2025
High mobility group protein 2 (HMGA2) is highly expressed in a broad range of benign and malignant tumorsViktoria Chirico, Fatih Baybars Ergüven, Katharina Möller, et al.
Diagnostics (Basel, Switzerland)|August 14, 2025
HMGB1 Deficiency Occurs in a Broad Range of Human Cancers and Is Often Associated with Unfavorable Tumor PhenotypeViktoria Chirico, Hena Sharifi, Maria Christina Tsourlakis, et al.
BMC Urology|April 24, 2024
PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitorsHenning Plage, Kira Furlano, Sebastian Hofbauer, et al.
Biomarker Research|December 10, 2024
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samplesSeyma Büyücek, Nina Schraps, Anne Menz, et al.
Diagnostic Pathology|January 13, 2024
Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entitiesFlorian Viehweger, Carola Böcker, Sören Weidemann, et al.
The American Journal of Surgical Pathology|August 12, 2024
Prevalence of S-methyl-5'-thioadenosine Phosphorylase (MTAP) Deficiency in Human Cancer: A Tissue Microarray Study on 13,067 Tumors From 149 Different Tumor TypesNatalia Gorbokon, Niklas Wößner, Maximilian Lennartz, et al.
Plos One|April 2, 2025
Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumorsSeyma Büyücek, Florian Viehweger, Viktor Reiswich, et al.
Pageof 12

Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Laboratory Investigation; a Journal of Technical Methods and Pathology|January 29, 2022
Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligenceDavid Dum, Tjark L C Henke, Tim Mandelkow, et al.
Scientific Reports|August 9, 2023
Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroidMaximilian Lennartz, Henrietta Csomós, Viktoria Chirico, et al.
Plos One|June 28, 2023
CELA3B immunostaining is a highly specific marker for acinar cell carcinoma of the pancreasRia Uhlig, Nina Bröker, Sören Weidemann, et al.
Virchows Archiv : an International Journal of Pathology|June 15, 2025
High mobility group protein 2 (HMGA2) is highly expressed in a broad range of benign and malignant tumorsViktoria Chirico, Fatih Baybars Ergüven, Katharina Möller, et al.
Diagnostics (Basel, Switzerland)|August 14, 2025
HMGB1 Deficiency Occurs in a Broad Range of Human Cancers and Is Often Associated with Unfavorable Tumor PhenotypeViktoria Chirico, Hena Sharifi, Maria Christina Tsourlakis, et al.
BMC Urology|April 24, 2024
PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitorsHenning Plage, Kira Furlano, Sebastian Hofbauer, et al.
Biomarker Research|December 10, 2024
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samplesSeyma Büyücek, Nina Schraps, Anne Menz, et al.
Diagnostic Pathology|January 13, 2024
Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entitiesFlorian Viehweger, Carola Böcker, Sören Weidemann, et al.
The American Journal of Surgical Pathology|August 12, 2024
Prevalence of S-methyl-5'-thioadenosine Phosphorylase (MTAP) Deficiency in Human Cancer: A Tissue Microarray Study on 13,067 Tumors From 149 Different Tumor TypesNatalia Gorbokon, Niklas Wößner, Maximilian Lennartz, et al.
Plos One|April 2, 2025
Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumorsSeyma Büyücek, Florian Viehweger, Viktor Reiswich, et al.
Pageof 12